The Genetics of Investing: Kill the Messenger

By: Doug Hornig | Thu, Sep 9, 2010
Print Email

If you had a previously incurable genetic condition and scientists came up with a treatment for it, you'd jump at the chance to take advantage. That's a no-brainer. But what if you had the opportunity to invest in a company deeply involved in just such cutting-edge research?

In classical drama, as well as real life, the bearer of bad news is often executed, simply for having brought it; in modern medicine, though, messenger killing is not only acceptable, it represents a major breakthrough in our approach to genetic disorders.

And major may be a vast understatement. We're talking about a development that could not only revolutionize an entire field and save countless lives, but one that will make fortunes for savvy investors.

It boils down to this: Scientists now have a technique for selectively, and reversibly, turning off the behavior of certain pieces of the genetic code in humans. The key word being reversibly.

Ever since the mapping of the human genome in recent years, researchers have been digging ever deeper into the genetic causes of many diseases. The idea was simple: find the gene responsible for a malady, then alter or remove it from a person's body and cure the disease. A severe course of action, but one many patients were willing to risk for the chance to cure a dreadful condition. In the 1990s, using a number of techniques collectively known as gene therapy, doctors started putting these new treatments into practice.

But the gene therapy route involves genetic mutation, a risky proposition at best... After you've deconstructed the gene, you can't put it back together if problems develop, which they often did. The genetic manipulations that were performed unleashed all kinds of side effects - many of them lethal. Too many people were dying, so scientists began looking beyond full-bore genetic assaults.

There had to be a better way, and there is...

The current preferred alternative - as yet still in its infancy - is about as close to the polar opposite of the old approach as possible. It doesn't touch the gene at all. It's not only temporary and easily reversible, and thus good for the patient's peace of mind, it's also well suited for experimentation on outside threats such as cancer, or possibly even bacterial and viral infections.

It's called RNA interference (RNAi), and as the name implies, the technique involves interrupting the function of RNA (ribonucleic acid), one of the key components of all living cells. In order to understand exactly how it works, you first have to know just a little about an extraordinarily complicated subject, human cell dynamics. Here's the short version.

At the center of the cellular action is the familiar, twisted-ladder-shaped double helix structure known as DNA (deoxyribonucleic acid). It consists of two very long chains of molecules (polynucleotides), paired together. One chain is called the sense strand; its complement on the other side is called the anti-sense strand.

DNA is further subdivided into 23 chromosomes, and they in turn are sliced into about 25,000 smaller bits called genes.

Genes are the source of all top-level commands in the body. They direct the production of proteins that make everything run smoothly or, in the case of a genetic malfunction, run amok. And they do it through a two-part process, transcription and translation.

First, transcription: Crawling all over the DNA are enzymes, little ladder-climbing robots that dock at the boundaries between genes. Once an enzyme locks on, it transcribes the code of a gene into a particular form of single-stranded RNA (or one half of a tiny piece of DNA). This RNA is always derived from the DNA's sense strand. It mimics the gene that encoded it, except for a small chemical marker that designates it as a "messenger" RNA (mRNA), a sort of carrier pigeon used to send genetic instructions from the command center of a cell to its parts.

Then, translation: The enzyme releases the mRNA, and it travels to another part of the cell, the ribosome, a kind of all-purpose life-maintenance factory. It's the ribosome that translates the instructions carried by the RNA and starts building proteins - the essential chemicals that support a healthy body - in accordance with the underlying DNA command.

Message sent; message received.

However, when the ribosome's protein production is not working correctly or is genetically faulty to begin with, the body essentially turns on itself. The mRNA is carrying the wrong message. This results in diseases that have been very difficult to treat compared with their virus- or bacteria-based counterparts.

Historically, fighting those diseases has been a matter of isolating the offending protein and neutralizing it. No small feat. There are about a hundred thousand different proteins in the body, interacting with each other in billions of ways. And once you find the one you're looking for, you have to test compound after compound against it, trying to identify the haystack needle that actually affects it (if there is one). Modern high-speed computers have simplified this random task, but it's still incredibly time consuming.

Now all that's changing - and the change is producing one of the most exciting developments in medicine today: anti-sense technology.

Once genetic mapping became a reality, researchers quickly discovered that it was possible to sabotage wayward mRNA before it ever gets to the ribosome. All you had to do was synthesize the anti-sense form of the undesirable mRNA and inject it into the cell, where it would bond with the sense sequence automatically, effectively "switching off" the message. If the ribosome can't read it, you've achieved RNA interference, and the offending proteins will never be produced at all.

You've killed the messenger.

That's excellent in itself. But the added bonus is reversibility. The effect lasts only as long as the anti-sense agent is present. If counterproductive complications arise, you simply stop treatment and the mRNA is returned to its previous state, once the supply of reacting chemicals is exhausted.

It works. But establishing the theoretical basis, then proving it out, those were the easy parts. Next came the difficulties, which divide into two broad areas.

Of these, the toughest is that you need a pinpoint delivery system. It's obviously impossible to inject the anti-sense compound into individual cells, one by one. Maybe in a Petri dish. But not in a human being.

Then, once you do get it inside, you have to protect it from the body's natural defenses against invaders. After that, it must encounter its target. Finally, it must align itself properly with the elaborately folded RNA and generate the enzymes that will deactivate it.

Thus there's a furious arms race underway, with plenty of companies vying to develop the gold standard in delivery systems. So far, there's no clear winner - though it looks like multiple options for delivery will eventually be available to therapy manufacturers, as recent successes using lipids and polymers to deliver anti-sense molecules in humans have demonstrated.

The other half of the equation is the need for the proper anti-sense sequences. But before you can synthesize them, you have to identify proteins associated with different diseases. That can be tricky. Protein signatures differ among diseases, and can even differ among patients with the same disease.

Zeroing in on the right target protein is not enough, either. You have to then backtrack to the mRNA that causes its production. Only then can you design your anti-sense messenger.

It's not high school lab work, but still... Lock down on the right mRNA and you don't need to bombard it with randomly chosen compounds. You only have to design one that features a complementary structure - properly combining the four simple molecules that are the building blocks of all DNA - and you're done. Comparatively, it's a walk on the beach. Not to mention that you don't have to tinker with the underlying gene, either.

Hand-crafted cures for nearly every genetic malady, possibly extending even to non-genetic ones - that's the promise. If only we didn't have to wait for a reliable delivery system to make its way through the scientific process and the regulatory gauntlet. But we do. In the meantime, however, researchers are taking great strides forward with mRNA identification and the development of specific anti-sense molecules. There's no reason not to stockpile them against the day when they can easily be applied.

And one innovative biotech company - the leader in the field of anti-sense therapy - is doing just that. Though it's only at the beginning of this exciting road, the company is already being courted by major pharmaceutical companies and bringing in tens of millions in revenue per year. As RNAi takes off, they stand to make billions, not only for themselves, but for investors as well. Try a no-risk subscription to Casey's Extraordinary Technology today - with 3-month money-back guarantee.



Doug Hornig

Author: Doug Hornig

Doug Hornig
Editor: Casey's Gold & Resource Report
Casey Research, LLC.

Doug Hornig

Doug Hornig joined the Casey team as a freelance writer on the former publication What We Now Know, a perfect fit for someone with his wide-ranging interests.  He wrote nearly 125 articles for WWNK between early 2004 and late 2007. In October of 2005, he assumed editorship of the Daily Resource column, to which was added Casey's Daily Resource Plus in 2007. A steady contributor to Casey's Gold & Resource Report, he also writes the occasional article for International Speculator and other Casey publications.

A former Edgar Award nominee, finalist for the Virginia Prize in both fiction and poetry, and a past winner of the Virginia Governor's Screenwriting competition, Doug lives on 30 mountainous acres in a county that just got its first stop light. He is an admitted political junkie, but hates all political parties. Doug has authored ten books and has written articles for Business Week and other renowned publications.

Information contained herein is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. The information contained herein is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. The opinions expressed herein are those of the publisher and are subject to change without notice. The information herein may become outdated and there is no obligation to update any such information. Doug Casey, entities in which he has an interest, employees, officers, family, and associates may from time to time have positions in the securities or commodities covered in these publications. Corporate policies are in effect that attempt to avoid potential conflicts of interest, and resolve conflicts of interest that do arise in a timely fashion. No portion of this web site may be extracted or reproduced without permission of the publisher.

Copyright © 2008-2013 Casey Research, LLC.

All Images, XHTML Renderings, and Source Code Copyright ©